- Johnson & Johnson's (JNJ, Financial) latest study results reveal a significant breakthrough in bladder cancer treatment.
- Analysts predict a potential price increase, with an average target of $170.64.
- Johnson & Johnson (JNJ) is rated "Outperform" with an estimated GF Value suggesting a 20.52% upside.
Johnson & Johnson (JNJ) has unveiled promising early results from their Phase 2b SunRISe-1 study, showcasing the efficacy of TAR-200. This treatment offers hope for patients with high-risk, BCG-unresponsive non-muscle-invasive bladder cancer. Impressively, over 80% of participants achieved disease-free survival, with the majority retaining their bladder, presenting TAR-200 as a viable alternative to surgical intervention.
Wall Street Analysts' Projections
In the analysis of 24 Wall Street professionals, the average price target for Johnson & Johnson (JNJ, Financial) stands at $170.64. The projections vary, with a high estimate of $185.00 and a low estimate of $150.00. This average target reflects a potential upside of 10.39% from its current trading price of $154.58. For more comprehensive estimate data, visit the Johnson & Johnson (JNJ) Forecast page.
Among 26 brokerage firms, Johnson & Johnson (JNJ, Financial) currently holds an "Outperform" rating with an average brokerage recommendation of 2.3. This rating is part of a scale ranging from 1 to 5, where 1 indicates a Strong Buy and 5 suggests a Sell position.
Assessing the GF Value
Per GuruFocus estimates, Johnson & Johnson's (JNJ, Financial) one-year GF Value is projected at $186.30. This reflects a potential upside of 20.52% from its present price point of $154.58. The GF Value represents GuruFocus' assessment of the fair market value of the stock, calculated based on historical trading multiples, prior business growth, and projected business performance. For a deeper dive into this data, please see the Johnson & Johnson (JNJ) Summary page.
